“Bullish on Divi's Laboratories for the medium term, with a target price of ₹8,300. The company is positioned as a CDMO leader, benefiting from the China+1 pharma supply chain shift and scaling up new capacity at Kakinada, ensuring steady earnings visibility with limited downside.”